Literature DB >> 6184404

Characterization of helper factors distinct from interleukin 2 necessary for the generation of allospecific cytolytic T lymphocytes.

R D Garman, D P Fan.   

Abstract

The in vitro generation of primary murine allospecific cytolytic T lymphocytes (CTL) from BALB/c (H-2d) spleen cell precursors in response to x-irradiated RDM4 (H-2k) tumor cells did not occur unless the cultures were supplemented with exogenous helper factors. Such CTL helper factors (CHF) could be provided by conditioned medium from cultures in which Sendai virus-immune BALB/c spleen cells were stimulated either with Sendai-infected cells (SC-CM) or with peptides cleaved by CNBr from intact virions (SP-CM). CHF activity stimulated by both antigens reached a maximum after day 3 of culture. In contrast, interleukin 2 (IL 2) activity peaked at day 2 and had essentially disappeared by day 4. Fractionation of day-4 SC-CM and SP-CM preparations by gel filtration revealed peaks of activity at apparent m.w. of 17,000 (CHF17) and 30,000 (CHF30). Under certain conditions, a peak of CHF activity appeared in the void volume with an apparent m.w. of 75,000 or greater. These results indicate that CHF activity is mediated by molecules distinct from IL 2.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6184404

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors.

Authors:  S Chouaib; J Chehimi; L Bani; N Genetet; T Tursz; F Gay; G Trinchieri; F Mami-Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

2.  Coxsackievirus B3-induced myocarditis. Autoimmunity is L3T4+ T helper cell and IL-2 independent in BALB/c mice.

Authors:  M Estrin; S A Huber
Journal:  Am J Pathol       Date:  1987-05       Impact factor: 4.307

3.  Coxsackievirus B-3 myocarditis. T-cell autoimmunity to heart antigens is resistant to cyclosporin-A treatment.

Authors:  M Estrin; C Smith; S Huber
Journal:  Am J Pathol       Date:  1986-11       Impact factor: 4.307

4.  Characterization of soluble factors that induce the cytolytic activity and the expression of T cell growth factor receptors of a T cell hybrid.

Authors:  F Erard; P Corthesy; K A Smith; W Fiers; A Conzelmann; M Nabholz
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

5.  Antigen-independent activation of cytotoxic T cells by lymphokines.

Authors:  L D Williams; W R McMaster; H S Teh
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

6.  HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro.

Authors:  P M Sondel; J A Hank; T Wendel; B Flynn; M J Bozdech
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

7.  Synergy between interleukin-2 and a second factor in the long-term growth of human T cells.

Authors:  B J Mills; J E Shively; P S Mitsky; D H Hawke; S J Forman; C L Wright; C W Todd
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

8.  Effects of interferon-gamma and tumour necrosis factor-alpha on the development of cytotoxic T lymphocytes in autologous mixed lymphocyte tumour cultures with human melanoma.

Authors:  A D Roth; F J Hornicek; C G Gerstner; J M Kirkwood
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

9.  Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4).

Authors:  M B Widmer; R B Acres; H M Sassenfeld; K H Grabstein
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

10.  B cell stimulatory factor 1 (interleukin 4) is sufficient for the proliferation and differentiation of lectin-stimulated cytolytic T lymphocyte precursors.

Authors:  J D Pfeifer; D T McKenzie; S L Swain; R W Dutton
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.